SunTrust Downgrades Allergen (AGN) to Neutral

Ackman Will Withdraw Request for Special Allergan (AGN) Meeting - CNBC

Pershing Squares Bill Ackman says he's withdrawing his request for a special Allergan (NYSE: AGN) meeting, according to CNBC.

Wells Fargo Downgrades Allergen (AGN) to Market Perform

Wells Fargo downgraded Allergen (NYSE: AGN) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $209.20 yesterday.

William Blair Downgrades Allergen (AGN) to Market Perform

William Blair downgraded Allergen (NYSE: AGN) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $209.20 yesterday.

Guggenheim Downgrades Allergen (AGN) to Neutral on Takeover

Guggenheim downgraded Allergen (NYSE: AGN) from Buy to Neutral but raises its price target to $220.00 following the Actavis (ACT) acqusition.

For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.

Shares of Allergen closed at $209.20 yesterday.

Actavis (ACT) Agrees to Acquire Allergan (AGN) for ~$219/Share

(Updated - November 17, 2014 9:16 AM EST)

Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of Actavis shares on November 14, 2014, the transaction is valued at approximately $66 billion, or $219 per Allergan share. The combination will create one of the top 10 global pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than... More

Actavis (ACT), Allergan (AGN) Said Nearing $62.5B Deal (VRX)

Actavis plc (NYSE: ACT) is said to be near a $62.5 billion deal to acquire Allergan (NYSE: AGN).

Bloomberg said Sunday that the deal, which as Actavis paying just over $210 per share for... More